X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (139) 139
humans (124) 124
surgery (111) 111
female (92) 92
oncology (91) 91
middle aged (87) 87
male (84) 84
aged (64) 64
cancer (59) 59
melanoma (57) 57
adult (49) 49
survival (49) 49
retrospective studies (42) 42
analysis (39) 39
prognosis (39) 39
melanoma - pathology (32) 32
metastasis (31) 31
article (30) 30
chemotherapy (29) 29
tumors (29) 29
medicine & public health (27) 27
surgical oncology (27) 27
abridged index medicus (26) 26
neoplasm staging (26) 26
risk factors (24) 24
biopsy (23) 23
mortality (23) 23
patients (23) 23
aged, 80 and over (21) 21
cohort studies (21) 21
follow-up studies (21) 21
skin neoplasms - pathology (21) 21
animals (20) 20
survival rate (20) 20
metastases (17) 17
multivariate analysis (17) 17
cancer surgery (16) 16
outcomes (16) 16
research (16) 16
treatment outcome (16) 16
lymphatic metastasis (15) 15
lymphatic system (15) 15
mice (15) 15
morbidity (15) 15
cell line, tumor (14) 14
databases, factual (14) 14
health aspects (14) 14
prognostic-factors (14) 14
sentinel lymph node biopsy (14) 14
care and treatment (13) 13
dermatology (13) 13
management (13) 13
melanoma - genetics (13) 13
patient outcomes (13) 13
radiotherapy (13) 13
therapy (13) 13
diagnosis (12) 12
melanoma - drug therapy (12) 12
sarcoma (12) 12
united-states (12) 12
cell biology (11) 11
cutaneous melanoma (11) 11
logistic models (11) 11
lymph nodes (11) 11
survival analysis (11) 11
american joint committee (10) 10
databases (10) 10
impact (10) 10
medical prognosis (10) 10
metastatic melanoma (10) 10
mitotic rate (10) 10
united states - epidemiology (10) 10
braf (9) 9
cancer therapies (9) 9
chemotherapy, adjuvant (9) 9
incidence (9) 9
lymphocytes (9) 9
mutation (9) 9
risk (9) 9
time factors (9) 9
united states (9) 9
usage (9) 9
adenocarcinoma (8) 8
age factors (8) 8
cells (8) 8
fluorescence (8) 8
lymph nodes - pathology (8) 8
medical colleges (8) 8
pathology (8) 8
postoperative complications (8) 8
postoperative complications - epidemiology (8) 8
protein kinase inhibitors - pharmacology (8) 8
radiation (8) 8
radiation therapy (8) 8
resection (8) 8
risk assessment (8) 8
stomach neoplasms - surgery (8) 8
t cells (8) 8
young adult (8) 8
acquired-resistance (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Surgical Oncology, ISSN 1068-9265, 08/2019, Volume 26, Issue 8, pp. 2322 - 2324
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 10/2019
Journal Article
ANNALS OF SURGICAL ONCOLOGY, ISSN 1068-9265, 08/2019, Volume 26, Issue 8, pp. 2322 - 2324
Journal Article
Annals of Surgery, ISSN 0003-4932, 09/2018, p. 1
Journal Article
Annals of Surgery, ISSN 0003-4932, 08/2019, Volume 270, Issue 2, pp. e25 - e25
Journal Article
Annals of surgery, 08/2019, Volume 270, Issue 2, p. e25
Journal Article
Nature, ISSN 0028-0836, 05/2017, Volume 545, Issue 7652, pp. 60 - 65
Despite the success of monotherapies based on blockade of programmed cell death 1 (PD-1) in human melanoma, most patients do not experience durable clinical... 
CRITERIA | MELANOMA | PEMBROLIZUMAB | IMMUNE CHECKPOINT BLOCKADE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | BRAF INHIBITORS | CHRONIC VIRAL-INFECTION | CANCER-THERAPY | IPILIMUMAB | EXHAUSTION | CD8-Positive T-Lymphocytes - cytology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - blood supply | Humans | Ki-67 Antigen - metabolism | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Melanoma - pathology | Phenotype | Antibodies, Monoclonal, Humanized - administration & dosage | Ki-67 Antigen - immunology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Melanoma - immunology | Melanoma - drug therapy | CD8-Positive T-Lymphocytes - metabolism | Female | Programmed Cell Death 1 Receptor - immunology | Antibodies, Monoclonal, Humanized - immunology | CD8-Positive T-Lymphocytes - immunology | Neoplasm Staging | Tumor Burden - immunology | Oncology, Experimental | Melanoma | Physiological aspects | Research | T cells | Tumors | Apoptosis | Cancer | Profiling | PD-1 protein | CD8 antigen | Medical services | Clinical trials | Lymphocytes T | Blood | Metastases | Immunology | Lymphocytes | Immunotherapy | Peripheral blood | Pretreatment | Medical research | Immunoglobulins | T cell receptors | Pharmacology | Patients | Pathology | Cell death | PD-L1 protein | Infiltration
Journal Article
Nature, ISSN 0028-0836, 08/2018, Volume 560, Issue 7718, pp. 382 - 386
Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1... 
CELLS | MELANOMA | PEMBROLIZUMAB | EXTRACELLULAR VESICLES | MULTIDISCIPLINARY SCIENCES | RESISTANCE | INDUCE APOPTOSIS | EXPRESSION | T-LYMPHOCYTES | NECK-CANCER | CHECKPOINT BLOCKADE | Exosomes - metabolism | Tumor Escape - drug effects | Prognosis | Humans | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Case-Control Studies | Neoplasm Metastasis | Immune Tolerance - immunology | Antibodies, Monoclonal, Humanized - pharmacology | Female | Immune Tolerance - drug effects | Tumor Escape - immunology | Antibodies, Monoclonal, Humanized - therapeutic use | Melanoma - pathology | B7-H1 Antigen - immunology | Disease Progression | Antineoplastic Agents, Immunological - pharmacology | Xenograft Model Antitumor Assays | B7-H1 Antigen - metabolism | Animals | B7-H1 Antigen - blood | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - immunology | Mice, Nude | CD8-Positive T-Lymphocytes - drug effects | Interferon-gamma - immunology | Melanoma - drug therapy | Cell Line, Tumor | Mice | Programmed Cell Death 1 Receptor - immunology | CD8-Positive T-Lymphocytes - immunology | Interferon-gamma - blood | Viral antibodies | Immunosuppression | Antibodies | Metastasis | Research | T cells | Properties | Biological response modifiers | Therapy | PD-1 protein | CD8 antigen | Lymphocytes T | Exosomes | Cancer therapies | Metastases | Skin cancer | Proteins | Vesicles | Lymphocytes | Immunotherapy | Immune system | Immunoglobulins | Melanoma | Immunosurveillance | T cell receptors | Patients | Immune checkpoint | Microscopy | PD-L1 protein | Ligands | Interferon | Head & neck cancer | Tumors | Apoptosis
Journal Article
Journal Article
Annals of surgical oncology, ISSN 1068-9265, 09/2019
Sentinel lymph node biopsy (SLNB) has been somewhat controversial for patients with a diagnosis of thick (> 4 mm) melanoma. This study aimed to characterize... 
Journal Article
Journal of Surgical Oncology, ISSN 0022-4790, 02/2019, Volume 119, Issue 2, pp. 232 - 241
Formally described in the 1960s, melanoma of unknown primary (MUP) is characterized by the finding of metastatic melanoma within the lymph nodes, subcutaneous... 
melanoma occult primary | unknown primary | malignant melanoma | melanoma regression | UNITED-STATES | SURGERY | PROGNOSTIC-FACTORS | PRIMARY SITE | LYMPH-NODES | IMPROVED SURVIVAL | PRIMARY ORIGIN | AMERICAN JOINT COMMITTEE | METASTATIC MALIGNANT-MELANOMA | ONCOLOGY | ENDOGENOUS IMMUNE-RESPONSE | STAGE MELANOMA
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2013, Volume 123, Issue 5, pp. 2155 - 2168
Journal Article
Surgery (United States), ISSN 0039-6060, 2019
Background: Complex cancer operations performed at high-volume and teaching hospitals have been associated with better outcomes. The purpose of this study was... 
Journal Article
Journal of the American College of Surgeons, ISSN 1072-7515, 10/2017, Volume 225, Issue 4, pp. S189 - S189
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2016, Volume 126, Issue 5, pp. 1834 - 1856
Targeting multiple components of the MAPK pathway can prolong the survival of patients with BRAF(V600E) melanoma. This approach is not curative, as some... 
MEDICINE, RESEARCH & EXPERIMENTAL | OXIDATIVE-PHOSPHORYLATION | CELLS | ONCOGENE | MELANOMA | MEK INHIBITION | PGC1-ALPHA | IMPROVED SURVIVAL | BRAF | STRESS | VEMURAFENIB | Humans | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Guanidines - pharmacology | Male | Neoplasm Proteins - antagonists & inhibitors | Mitochondrial Proteins - genetics | Extracellular Signal-Regulated MAP Kinases - metabolism | Neoplasm Proteins - metabolism | Extracellular Signal-Regulated MAP Kinases - genetics | DNA-Binding Proteins - metabolism | Mitochondria - genetics | Melanoma - genetics | Mitochondrial Proteins - metabolism | Female | HSP90 Heat-Shock Proteins - genetics | Neoplasm Proteins - genetics | Melanoma - metabolism | Mitochondria - metabolism | Melanoma - pathology | Mitochondria - pathology | Transcription Factors - genetics | DNA-Binding Proteins - genetics | Lactams, Macrocyclic - pharmacology | Transcription Factors - metabolism | Animals | Mitochondrial Dynamics - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Melanoma - drug therapy | HSP90 Heat-Shock Proteins - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Mitochondrial biogenesis | Research | Drug resistance | Analysis | Extracellular signal-regulated kinases | Phosphorylation | Melanoma | Mitochondrial DNA | Biosynthesis | Genomes | Kinases | Metabolism | Gene expression | Studies | Protein folding | Tumors | Cancer
Journal Article
Cell Reports, ISSN 2211-1247, 09/2013, Volume 4, Issue 6, pp. 1090 - 1099
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.